Digestive Enzymes for Bloating

Verdict: Works only for the matched sugar, not general bloating

Digestive enzymes help only when matched to a specific trigger sugar: lactase for lactose and alpha-galactosidase for beans can ease the related gas, but the generic multi-enzyme blends most people buy for everyday bloating have little reliable evidence behind them.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is weak because the evidence splits sharply by enzyme. Targeted, substrate-specific enzymes have niche support: in lactose-intolerant patients, lactase cut cumulative breath hydrogen by about 55% and improved symptom scores (PMID 33490624), and alpha-galactosidase reduced bean-related gas and breath hydrogen (PMID 17151807), even cutting days of moderate-to-severe bloating in a small pediatric trial (PMID 24063420).

But the effect is mostly on flatulence, not bloating itself, and it does not generalize. The 1994 Beano trial reduced gas frequency yet found no significant change in bloating or pain (PMID 7964541), the pediatric study showed no effect on distension (PMID 24063420), and a 2021 crossover in IBS patients was outright negative (PMID 33619835). All trials are small (n=8 to 120), and no meta-analysis exists for bloating as a standalone symptom.

Crucially, the generic multi-enzyme blends sold for nonspecific bloating rest only on small functional-dyspepsia trials that did not enroll bloating patients or isolate bloating as an endpoint, one of which tested the maker's own product (PMID 37976892; PMID 30156436, industry-funded). Regulators (FDA, NHS, WHO) endorse only prescription pancreatic enzymes for diagnosed pancreatic insufficiency, a different drug and condition, and Mayo Clinic stays cautious about broad use, so the popular over-the-counter claim earns only a weak, warning-flagged rating.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L5 Clinical bodiesAuthoritative stance
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.472
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (7)L2 · primary research & systematic reviews

The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms
PMID: 17151807 2007 RCT (double-blind) n = 8
Finding: The 1200 GalU dose produced a significant reduction in both breath hydrogen excretion and severity of flatulence; both doses reduced overall gas-related symptom scores. Very small healthy-volunteer challenge study.
🟠 Limited quality Effect size: Significant reduction in breath H2 and flatulence severity at 1200 GalU (exact CI not reported in abstract)
View on PubMed
Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance
PMID: 7964541 1994 RCT (double-blind) n = 19
Finding: Flatulence frequency was significantly reduced versus placebo (F=2.87, p=.016), with the difference reaching significance at the 5th post-meal hour. Notably, NO significant difference was seen for bloating or pain between groups.
🟠 Limited quality Effect size: Flatulence reduced (p=.016); bloating and pain NS
View on PubMed
Efficacy and tolerability of alpha-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial
PMID: 24063420 2013 RCT (double-blind) n = 52
Finding: alpha-galactosidase significantly reduced global distress (p=0.02), decreased days with moderate-to-severe bloating (p=0.03) and the proportion of patients with flatulence (p=0.02). No effect on abdominal spasms or abdominal distension. No adverse events.
Effect size: Days with moderate-severe bloating reduced (p=0.03); distension NS
View on PubMed
A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme alpha-galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients
PMID: 33619835 2021 RCT (double-blind) n = 20
Finding: Neither GI symptom ratings nor hydrogen/methane concentrations differed significantly between alpha-galactosidase and placebo. Abdominal pain and bloating severity fell the next morning in BOTH arms with no between-group difference — alpha-galactosidase was not superior to placebo in IBS patients.
Effect size: No significant difference vs placebo (negative trial)
View on PubMed
Effect of lactase on symptoms and hydrogen breath levels in lactose intolerance: A crossover placebo-controlled study
PMID: 33490624 2020 RCT (double-blind) n = 47
Finding: Oral lactase significantly improved clinical symptoms and mean clinical score (p<0.05) and cut cumulative hydrogen breath excretion by 55% versus placebo over 180 minutes. Supports lactase for lactose-related bloating/gas specifically.
Effect size: 55% reduction in cumulative breath H2; symptom score improved (p<0.05)
View on PubMed
Efficacy of digestive enzyme supplementation in functional dyspepsia: A monocentric, randomized, double-blind, placebo-controlled, clinical trial
PMID: 37976892 2023 RCT (double-blind) n = 120
Finding: The enzyme group showed improvement in NDI-SF, VAS pain and PSQI sleep scores versus placebo, and the supplement was well tolerated. Population is functional dyspepsia (postprandial fullness/upper-GI), not primary bloating; bloating was not reported as a discrete outcome.
Effect size: Significant improvement in dyspepsia QoL/pain scores; bloating not separately quantified
View on PubMed
Evaluation of the Safety and Efficacy of a Multienzyme Complex in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study
PMID: 30156436 2018 RCT (double-blind) n = 40
Finding: Multienzyme complex significantly improved a composite of GI symptoms including bloating (score 7.3 to 2.6 vs placebo 7.6 to 5.6, p=0.0033). Small trial; DigeZyme is the manufacturer's (Sabinsa) own branded product, so industry conflict of interest is present.
🟠 Limited quality ⚠️ Industry-funded Effect size: Composite GI symptom score improved (p=0.0033); bloating part of composite, not isolated
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
CREON is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. source↗
L4b EU EFSA
Neutral
L4c UK NHS
Supportive
PERT replaces the enzymes that your pancreas would normally make. PERT comes as capsules that you take when you eat and helps you digest your food by breaking down carbohydrates, fats and proteins. PERT is available on the NHS with brand names including Creon, Nutrizym and Pancrex. source↗
L4d TW TFDA / 衛福部
Neutral
胰臟酵素製劑「卡利消」全台缺貨,是醫療級胰臟酵素,適用於胰臟外分泌功能不足、慢性胰臟炎、胰臟切除後、先天性胰臟功能障礙等患者……食藥署已啟動專案輸入,尋找國外已上市但台灣未引進的同成分藥品,且已有廠商提出申請。 source↗
L4e WHO
Supportive
Pancreatic enzymes are on the World Health Organization's List of Essential Medicines. Pancreatin is a mixture of several digestive enzymes produced by the exocrine cells of the pancreas, composed of amylase, lipase and protease, used to treat conditions in which pancreatic secretions are deficient, such as surgical pancreatectomy, pancreatitis and cystic fibrosis. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Alpha-galactosidase (Beano, BeanAssist, others) helps break down carbohydrates in beans and other vegetables. source↗
L5c Cleveland Clinic
Cautious
L5d Harvard Health
Cautious
L5e Specialty Society (condition-mapped)
Neutral
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬7 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-bloating-INT-digestive-enzymes-001 繁體中文版 →